Bactiguard recruits global Vice President Sales
Jonas Östregård, who has extensive sales experience from various positions at Astra Zeneca, has been recruited to a new global role as Vice President Sales at Bactiguard. He will join in August 2018 and report to the CEO.
”Jonas Östregård has extensive international sales experience from Europe and Asia. He has spent most of his career in the demanding pharmaceutical industry, both as a line manager and project lead in AstraZeneca’s multicultural environment, and delivered tangible results. The combination of a strong commercial drive, strategic edge, people management skills and a pragmatic leadership style makes him very well suited to lead Bactiguard’s sales organization to the next level. Therefore I am very pleased to welcome Jonas on board”, says Christian Kinch CEO.
Jonas Östregård, aged 43, has held various senior commercial positions at Astra Zeneca, where he started his career as a sales representative in 2002. Prior to joining AstraZeneca he ran his own consultancy in leadership and communication. He has a Master degree in Business, Administration and Economics from Stockholm School of Business at Stockholm University.
Jonas Östregård joins Bactiguard in August and will lead the sales organization, which consists of regional sales directors, sales representatives and external distributors. He will report to the CEO and be responsible for developing global sales strategies and processes.
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com
